{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T09:21:58Z","timestamp":1769851318875,"version":"3.49.0"},"reference-count":38,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Cytogenetic abnormalities and the persistence of minimal residual disease (MRD) following autologous stem cell transplantation (ASCT) are two established prognostically unfavorable biomarkers in multiple myeloma (MM). Previous studies have shown that post-transplant MRD status is a powerful predictor of progression-free survival (PFS) and overall survival (OS). However, the impact of MRD remains poorly characterized in MM patients with high- or ultra-high-risk cytogenetics. Objectives: This study investigated the prognostic value of post-transplant MRD in standard- versus high- and ultra-high-risk MM. To this aim, we performed a retrospective analysis of 137 MM patients who underwent high-dose chemotherapy (HDCT) and ASCT at our institution between January 2019 and December 2021. Cytogenetics were assessed by fluorescence in situ hybridization. High-risk genomic alterations included del(17p), t(4;14), t(14;16), t(14;20), gain(1q), and TP53 mutations, with two or more alterations defining the ultra-high-risk category. MRD was assessed in bone marrow aspirates post-ASCT using flow cytometry. Results: Eighty-two (60%) patients were categorized as being at standard risk, forty (29%) as high risk, and fifteen (11%) as ultra-high risk. Median follow-up was 47 months. MRD negativity was achieved in 76 (55%) patients. At 48 months, the overall PFS rate was 61% (72%, 50%, and 32% for the standard-, high-, and ultra-high-risk subgroups, respectively; p = 0.0004), while the OS rate was 85% (89%, 79%, and 80% in standard-, high-, and ultra-high-risk MM patients, respectively; p = 0.1494). Within the standard-risk subgroup, longer PFS was observed for patients achieving MRD negativity (p = 0.0172). High- and ultra-high-risk patients showed no significant differences in PFS when stratified by MRD status, possibly due to prompt progression to MRD positivity. Conclusions: Our results suggest that high- and ultra-high-risk MM patients might benefit from closer response monitoring, including dynamic MRD assessment. Further, high- and ultra-high-risk patients might require a more intensive peri-transplant treatment.<\/jats:p>","DOI":"10.3390\/cancers17091565","type":"journal-article","created":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T20:09:14Z","timestamp":1746389354000},"page":"1565","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic Value of Post-Transplant MRD Negativity in Standard Versus High- and Ultra-High-Risk Multiple Myeloma Patients"],"prefix":"10.3390","volume":"17","author":[{"given":"Lea Jasmin","family":"K\u00fcndgen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University of Bern, CH-3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1639-3059","authenticated-orcid":false,"given":"Dilara","family":"Akhoundova","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University of Bern, CH-3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University of Bern, CH-3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Legros","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Inselspital, University of Bern, CH-3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Shaforostova","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University of Bern, CH-3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-1573","authenticated-orcid":false,"given":"Katja","family":"Seipel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University of Bern, CH-3010 Bern, Switzerland"},{"name":"Department for Biomedical Research (DBMR), University of Bern, CH-3008 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-947X","authenticated-orcid":false,"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[{"name":"Department of Hematology, Inselspital, University of Bern, CH-3010 Bern, Switzerland"},{"name":"Center of Laboratory Medicine (ZLM), Inselspital, University of Bern, CH-3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University of Bern, CH-3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple Myeloma","volume":"397","author":"Pawlyn","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","article-title":"High-Risk Disease in Newly Diagnosed Multiple Myeloma: Beyond the R-ISS and IMWG Definitions","volume":"12","author":"Hagen","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple Myeloma: 2022 Update on Diagnosis, Risk Stratification, and Management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.hoc.2023.12.009","article-title":"Measurable Residual Disease and Decision-Making in Multiple Myeloma","volume":"38","author":"Derman","year":"2024","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.bbmt.2017.01.076","article-title":"Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics","volume":"23","author":"Chakraborty","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter Flow Cytometric Remission Is the Most Relevant Prognostic Factor for Multiple Myeloma Patients Who Undergo Autologous Stem Cell Transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-Risk Cytogenetics and Persistent Minimal Residual Disease by Multiparameter Flow Cytometry Predict Unsustained Complete Response after Autologous Stem Cell Transplantation in Multiple Myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic Value of Deep Sequencing Method for Minimal Residual Disease Detection in Multiple Myeloma","volume":"123","author":"Lahuerta","year":"2014","journal-title":"Blood"},{"key":"ref_15","unstructured":"(2024, November 04). Risky Business: Examining the Challenge with Defining High-Risk and Ultra High\u2013Risk Multiple Myeloma. Available online: https:\/\/dailynews.ascopubs.org\/doi\/10.1200\/ADN.23.201523."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","article-title":"Minimal Residual Disease in Myeloma by Flow Cytometry: Independent Prediction of Survival Benefit per Log Reduction","volume":"125","author":"Rawstron","year":"2015","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00277-019-03609-x","article-title":"Achieving Minimal Residual Disease-Negative by Multiparameter Flow Cytometry May Ameliorate a Poor Prognosis in MM Patients with High-Risk Cytogenetics: A Retrospective Single-Center Analysis","volume":"98","author":"Li","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of Minimal Residual Disease with Superior Survival Outcomes in Patients with Multiple Myeloma: A Meta-Analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/10428194.2018.1485908","article-title":"High-Risk Myeloma and Minimal Residual Disease Postautologous-HSCT Predict Worse Outcomes","volume":"60","author":"Hu","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/j.clml.2020.01.001","article-title":"Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study","volume":"20","author":"Kunacheewa","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"JCO"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","article-title":"Carfilzomib Significantly Improves the Progression-Free Survival of High-Risk Patients in Multiple Myeloma","volume":"128","author":"Fonseca","year":"2016","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of Outcome in Newly Diagnosed Myeloma: A Meta-Analysis of the Molecular Profiles of 1905 Trial Patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1097\/HS9.0000000000000831","article-title":"Impact of Ultra High-Risk Genetics on Real-World Outcomes of Transplant-Eligible Multiple Myeloma Patients","volume":"7","author":"Panopoulou","year":"2023","journal-title":"Hemasphere"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/10428194.2018.1473577","article-title":"Prolonged Survival with Increasing Duration of Lenalidomide Maintenance after Autologous Transplant for Multiple Myeloma","volume":"60","author":"Amsler","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.2022018339","article-title":"Optimizing the Value of Lenalidomide Maintenance by Extended Genetic Profiling: An Analysis of 556 Patients in the Myeloma XI Trial","volume":"141","author":"Panopoulou","year":"2023","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/s41375-020-0750-z","article-title":"Predicting Ultrahigh Risk Multiple Myeloma by Molecular Profiling: An Analysis of Newly Diagnosed Transplant Eligible Myeloma XI Trial Patients","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with Lenalidomide as Maintenance after Transplant in Newly Diagnosed Multiple Myeloma: The AURIGA Study","volume":"145","author":"Badros","year":"2024","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Dimopoulos, M.A., Sonneveld, P., Rodr\u00edguez-Otero, P., Quach, H., Ho, P.H., Beksac, M., Hulin, C., Antonioli, R., Leleu, X., and Mangiacavalli, S. (2024, January 13\u201316). Daratumumab (DARA)\/Bortezomib\/Lenalidomide\/Dexamethasone (D-VRd) with D-R Maintenance in Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Analysis of PERSEUS Based on Cytogenetic Risk. Proceedings of the 2024 European Hematology Association Annual Meeting, Madrid, Spain.","DOI":"10.1016\/S2152-2650(24)01889-5"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Mehl, J., Akhoundova, D., Bacher, U., Jeker, B., Rhyner Agocs, G., Ruefer, A., Soltermann, S., Soekler, M., Winkler, A., and Daskalakis, M. (2024). Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery. Cancers, 16.","DOI":"10.3390\/cancers16101854"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1080\/10428194.2022.2123229","article-title":"Single versus Tandem Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and High-Risk Cytogenetics. A Retrospective, Open-Label Study of the PETHEMA\/Spanish Myeloma Group (GEM)","volume":"63","author":"Villalba","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_35","first-page":"401","article-title":"Double Autologous Stem Cell Transplantation Significantly Prolongs Progression-Free Survival and Overall Survival in Comparison with Single Autotransplantation in Newly Diagnosed Multiple Myeloma: An Analysis of Phase 3 EMN02\/HO95 Study","volume":"130","author":"Cavo","year":"2017","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating Tumor Cells for the Staging of Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma","volume":"40","author":"Cedena","year":"2022","journal-title":"JCO"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, Presenting Features and Outcome of Extramedullary Disease in Multiple Myeloma: A Longitudinal Study on 1003 Consecutive Patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma (MASTER): Final Report of the Multicentre, Single-Arm, Phase 2 Trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1565\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:26:53Z","timestamp":1760030813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,4]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["cancers17091565"],"URL":"https:\/\/doi.org\/10.3390\/cancers17091565","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,4]]}}}